use
exist
drug
tempt
approach
acceler
everyth
target
host
protein
skirt
problem
antivir
drug
resist
also
open
possibl
scour
exist
drug
collect
field
cancer
use
exist
drug
tempt
approach
acceler
everyth
pleschka
say
pfizer
mek
inhibitor
alreadi
pass
phase
safeti
trial
candid
cancer
treatment
research
discontinu
chemotherapi
drug
mek
inhibitor
would
even
safer
influenza
treatment
planz
say
would
take
much
lower
dose
shorter
treatment
time
interfer
influenza
activ
normal
protein
need
block
mutant
protein
cancer
atriva
deriv
formul
compound
call
increas
cellular
uptak
drug
compani
plan
test
phase
studi
next
year
half
planz
say
phase
challeng
studi
volunt
purpos
infect
flu
undergo
treatment
far
behind
ludwig
planz
pleschka
also
consult
compani
recent
finish
phase
trial
anoth
antiinfluenza
drug
close
resembl
aspirin
inhibit
common
cancerdrug
target
nuclear
factor
nf
three
scientist
team
report
compound
block
signal
protein
activ
consequ
block
viral
replic
part
prevent
ribonucleoprotein
leav
cell
german
drug
compani
ventaleon
licens
idea
three
alreadi
patent
partnership
ukbas
pharmaceut
compani
vectura
ventaleon
conduct
phase
trial
hospit
patient
sever
influenza
result
trial
end
may
publish
planz
present
data
last
year
intern
influenza
meet
find
show
oseltamivir
administ
combin
inhibitor
taken
three
time
day
allevi
flu
symptom
rapidli
treatment
oseltamivir
alon
drug
inhal
effect
local
transient
make
safe
way
inhibit
ludwig
colleagu
one
capit
potenti
exploit
cancer
drug
target
screen
librari
small
molecul
virologist
deni
kainov
group
univers
helsinki
zero
chemotherapi
drug
call
gemcitabin
use
treat
varieti
cancer
includ
affect
bladder
pancrea
breast
last
year
demonstr
gemcitabin
block
viral
replic
immun
cell
call
macrophag
without
interf
express
antivir
gene
shortag
potenti
hostdirect
antivir
target
thank
largescal
screen
method
uncov
cellular
function
influenza
command
surviv
probe
thousand
human
gene
role
influenza
life
cycl
fluomic
research
use
rnabas
screen
halt
host
protein
product
complementari
dna
cdna
base
screen
ramp
studi
publish
group
use
short
interf
rna
sirna
silenc
gene
human
lung
cell
identifi
seem
necessari
influenza
viru
enter
cell
reproduc
fluomic
team
also
incorpor
data
set
describ
known
interact
viral
protein
human
protein
way
refin
sirna
data
search
best
drug
candid
scientist
work
erato
kawaoka
infectioninduc
host
respons
project
base
japan
scienc
technolog
agenc
kawaguchi
map
interact
viral
hostcel
protein
creat
network
relationship
call
interactom
use
result
select
gene
silenc
sirna
studi
publish
use
techniqu
winnow
result
two
protein
could
block
exist
chemotherapi
agent
call
halt
viral
technolog
sirna
screen
help
put
hostdirect
antivir
map
accord
ludwig
drug
furthest
along
pipelin
atriva
mek
inhibitor
come
strategi
exploit
inform
alreadi
known
influenza
life
cycl
exampl
ansun
biopharma
san
diego
develop
drug
prevent
influenza
viru
take
first
step
lung
cell
drug
fusion
protein
bind
lung
epitheli
cell
catalyz
reaction
caus
molecul
call
sialic
acid
viru
use
engag
cell
fall
cell
surfac
lop
viru
dock
site
compound
prevent
sever
strain
influenza
infect
cell
ansun
also
test
treatment
patient
influenza
phase
clinic
trial
meanwhil
vishwanath
lingappa
virologist
founder
prosetta
bioscienc
san
francisco
identifi
drug
target
work
opposit
end
influenza
life
cycl
viru
assembl
outer
coat
call
capsid
work
lab
univers
california
san
francisco
lingappa
sister
jaisri
found
virus
coopt
part
cellular
machin
reassembl
frankensteinstyl
viralcapsid
assembl
line
show
hiv
exampl
need
hostcel
protein
make
prosetta
vishwanath
lingappa
found
studi
process
test
tube
design
make
possibl
screen
compound
specif
block
frankensteinlik
form
host
protein
turn
product
new
viral
capsid
lingappa
colleagu
use
approach
select
compound
prevent
rabi
viru
produc
capsid
found
compound
could
also
block
viral
infect
prosetta
identifi
dozen
drug
block
influenza
viru
capsid
assembl
taken
one
drug
cell
cultur
anim
studi
lingappa
say
compound
also
block
respiratori
syncyti
viru
rat
coronaviru
pig
akhilesh
reddi
molecular
biologist
univers
cambridg
uk
approach
field
outsid
viral
life
cycl
entir
focus
instead
host
cell
circadian
rhythm
influenza
viru
total
depend
host
cell
replic
mammalian
cell
oper
circadian
rhythm
say
must
good
bad
time
day
infect
cell
machineri
need
replic
abund
one
time
day
anoth
time
day
say
studi
publish
last
septemb
team
report
cell
line
mice
suscept
infect
earli
day
thank
part
lower
level
cellular
protein
call
notabl
also
wane
human
blood
cell
winter
reddi
group
screen
compound
augment
product
say
could
mani
potenti
antivir
drug
target
among
cellclock
protein
given
cell
pathway
rhythmic
question
say
pathway
alter
safe
disrupt
clock
make
variou
manipul
nt
disrupt
clock
reddi
say
surpris
drug
target
hostcel
function
come
safeti
challeng
gener
concern
antivir
drug
must
job
without
harm
host
cell
interf
normal
immun
respons
garciasastr
say
import
side
coin
need
take
care
planz
say
atriva
cofound
spent
lot
effort
address
critic
mek
inhibit
strategi
given
molecul
involv
immun
respons
exampl
cell
use
mek
signal
prolifer
respons
infect
planz
point
specif
subtyp
cell
typic
fight
virus
type
helper
cell
expand
presenc
mek
inhibitor
direct
cellular
immun
respons
even
respons
favor
say
inhibit
planz
say
complet
human
trial
alreadi
demonstr
safeti
efficaci
like
say
inhal
drug
contribut
safeti
method
limit
lung
local
effect
also
key
safeti
target
sialic
acid
express
mani
differ
cell
type
collect
clinic
trial
influenza
respiratori
virus
compani
safe
test
drug
almost
patient
activ
drug
longliv
stop
viru
spread
human
lung
cell
begin
regener
sialic
acid
hour
exposur
ref
shortterm
absenc
viral
dock
site
enough
interrupt
viru
life
cycl
give
immun
system
time
get
leg
infect
goe
repurpos
cancer
drug
planz
say
take
much
higher
drug
concentr
longer
treatment
time
shut
pathway
tumor
normal
lung
cell
viru
intermitt
switch
pathway
hour
time
although
influenza
initi
drew
ludwig
back
virolog
say
atriva
stop
similarli
mani
hostdirect
antivir
compani
mek
inhibitor
act
sever
respiratori
virus
also
transport
protein
cell
nucleu
obviou
advantag
abl
treat
one
viral
infect
drug
exampl
might
offer
quick
remedi
emerg
infecti
diseas
recent
outbreak
ebola
zika
virus
demonstr
highli
specif
antivir
alway
develop
quickli
enough
put
use
event
outbreak
result
new
viru
come
along
nt
abil
treat
whatsoev
effect
come
brandnew
treatment
reddi
say
hostdirect
approach
focu
cell
function
pathway
commonli
hijack
mani
virus
would
suppli
immedi
target
kainov
kept
mind
choos
potenti
antivir
pursu
exampl
besid
influenza
viru
gemcitabin
inhibit
herp
simplex
viru
sindbi
march
colleagu
publish
studi
show
gemcitabin
well
two
antiinfluenza
drug
inhibit
zika
viru
growth
human
focus
develop
broadspectrum
hostdirect
drug
research
address
emerg
virus
zika
without
forget
constant
companion
influenza
ronald
moss
infectiousdiseas
specialist
serv
ceo
ansun
februari
say
although
sens
urgenc
surround
influenza
tend
wax
wane
alway
potenti
resistancecaus
mutat
surfac
pop
possibl
larger
scale
think
juri
still
whether
prepar
someth
like
